Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-cash Items (2022 - 2024)

Immunocore Holdings' Non-cash Items history spans 3 years, with the latest figure at $326.1 million for Q1 2024.

  • For Q1 2024, Non-cash Items changed N/A year-over-year to $326.1 million; the TTM value through Mar 2024 reached $326.1 million, changed N/A, while the annual FY2023 figure was $370.0 million, 10.07% up from the prior year.
  • Non-cash Items for Q1 2024 was $326.1 million at Immunocore Holdings, down from $370.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $370.0 million in Q4 2023 and bottomed at $326.1 million in Q1 2024.
  • The 3-year median for Non-cash Items is $336.1 million (2022), against an average of $344.1 million.
  • The largest YoY upside for Non-cash Items was 10.07% in 2023 against a maximum downside of 10.07% in 2023.
  • A 3-year view of Non-cash Items shows it stood at $336.1 million in 2022, then rose by 10.07% to $370.0 million in 2023, then fell by 11.85% to $326.1 million in 2024.
  • Per Business Quant, the three most recent readings for IMCR's Non-cash Items are $326.1 million (Q1 2024), $370.0 million (Q4 2023), and $336.1 million (Q4 2022).